Ypsomed Holding AG: history, ownership, mission, how it works & makes money

From its roots in the 2003 spin-out of Willy Michel's Disetronic Group to celebrating four decades of innovation in 2024, Ypsomed Holding AG has transformed into a global force in self‑medication devices - a publicly traded company on the SIX under YPSN with a market capitalization of about CHF 4.33 billion (Dec 12, 2025) and more than 2,800 employees (2025); strategic moves such as the April 2025 divestiture of its Diabetes Care division have sharpened focus on high‑growth Delivery Systems (which jumped 30.4% in fiscal 2024/25), while first‑half 2025/26 results showed Delivery Systems sales up 21% to CHF 267 million and a net profit of CHF 139.1 million, underpinning an improved equity ratio of 66.8% and a proposed dividend of CHF 2.20 per share - all as Ypsomed ramps global manufacturing in Germany, China and the U.S., secures partnerships with 31 GLP‑1 companies, and commits CHF 1.5 billion to nearly triple device capacity to 1 billion by decade‑end as it pursues mid‑term targets of CHF 0.9-1.2 billion in sales and CHF 280-340 million in EBIT by 2029/30.

Ypsomed Holding AG (0QLQ.L): Intro

• Founded from Disetronic breakup: 2003 (origins under Willy Michel)
• 40th anniversary celebrated: 2024
• Employees: >2,800 as of 2025
• Diabetes Care divestiture: April 2025
• Delivery Systems revenue growth (FY 2024/25): +30.4%
• Global manufacturing expansion (by Nov 2025): new sites in Germany, China, USA
• Capacity target: triple to 1 billion devices by 2030

• Project-based development contracts (one-time engineering, tooling, validation fees)
• High-volume manufacturing contracts for autoinjectors and complex drug-delivery devices
• Recurring supply agreements and device-as-a-service offerings (spares, maintenance, upgrades)
• Platform licensing and intellectual property commercialization

• Diabetes Care divestiture (Apr 2025): freed resources and simplified operations; Delivery Systems segment recorded +30.4% revenue growth in FY 2024/25.
• Manufacturing expansion (Nov 2025): new plants in Germany, China and the U.S. to meet demand and localize supply; capacity goal of 1 billion devices by decade-end.
• Employee growth to >2,800 (2025): supports R&D, regulatory, production and customer project execution globally.

Ypsomed Holding AG (0QLQ.L): History

• Listed on the SIX Swiss Exchange under the ticker YPSN (0QLQ.L).
• Diverse shareholder base; no single client contributes more than 15% of revenue, supporting revenue stability and reduced concentration risk.
• Market capitalization: ~CHF 4.33 billion (as of 12 December 2025).

• Ownership structure highlights:
  • Publicly traded with institutional and retail investors across Europe and globally.
  • Ownership concentrated enough to ensure strategic continuity, yet diversified to limit single-client revenue risk.
• Corporate governance and shareholder returns:
  • Board of Directors proposed CHF 2.20 dividend for FY 2024/25 (10% increase).
  • Strong equity ratio (66.8%) reflects low leverage and a conservative balance sheet policy.

• How Ypsomed makes money:
  • Product sales: reusable and disposable insulin pens, pen needles, infusion sets, and injection devices sold to pharmaceutical companies and healthcare providers.
  • Contract manufacturing and development services for pharma clients (device development, tooling, assembly).
  • Connected devices and digital services for diabetes management, driving recurring revenue and differentiation.

Ypsomed Holding AG (0QLQ.L): Ownership Structure

• Mission and values: patient-centricity, innovation, operational excellence, sustainability and regulatory quality.
• Strategic priorities: expand global manufacturing capacity, increase R&D investment, and scale sustainable device platforms (YpsoDot, YpsoFlow, YpsoLoop).
• Environmental commitment: design for recyclability and reduced lifecycle impact across device platforms.
• Capital allocation: disciplined reinvestment in capacity and R&D while maintaining a dividend policy to return value to shareholders.

• Product sales: proprietary devices (autoinjectors, pen injectors, infusion pumps) sold directly and via OEM partnerships.
• Contract manufacturing & development (CDMO): device design, industrialization and manufacturing services for pharmaceutical and biotech companies.
• Connected-health services: value-added digital offerings and data integration that complement device sales and after‑sales revenue.

• Founders/management and related parties hold a significant block-aligning long-term operational focus with shareholder interests.
• Free float held by institutional and retail investors provides market liquidity.

Ypsomed Holding AG (0QLQ.L): Mission and Values

• Ypsomed Delivery Systems (YDS): development and manufacturing of pen injectors, auto-injectors and wearable injectors (mechanical and electromechanical) sold as proprietary products and via development/manufacturing partnerships under the YDS brand.
• Ypsomed Diabetes Care: patient-facing diabetes management products under the mylife brand, including insulin pumps, infusion sets, pen needles, blood glucose monitoring systems and connected diabetes services.
• Others: services, spare parts, accessories, and digital offerings that complement device sales and recurring consumables revenue.

• Strategic partnerships: agreements with 31 pharmaceutical companies to support GLP‑1 and other injectable therapies, positioning Ypsomed as a major contract partner in the pharma value chain.
• Manufacturing footprint: production sites in Switzerland (corporate R&D and HQ), Germany, China and the United States to support regional supply, regulatory compliance and scale-up for high-volume launches.
• Product portfolio: pen injectors, disposable and reusable auto-injectors, wearable injectors for larger-volume/extended infusions, insulin pumps (mylife YpsoPump family), infusion sets, pen needles and blood glucose monitoring systems.
• Innovation & sustainability: ongoing investments in new device platforms (wearables, electromechanical pens), digital integration (connected pumps and apps), and sustainable manufacturing expansions to meet rising demand for GLP‑1 therapies and chronic care devices.

• Device sales: sale of branded devices (mylife) and bespoke devices to pharmaceutical companies (YDS) - one-time and launch-related revenues.
• Consumables & accessories: recurring revenue from infusion sets, pen needles, cartridges and other disposables tied to device ecosystems.
• Development & manufacturing services: contract development, device customization and manufacturing-for-hire for pharmaceutical partners-especially for GLP‑1 injectable programs.
• Digital services & support: software, connectivity, training, and value-added services that enhance device adoption and support long-term patient engagement.
• Geographic diversification: sales across Europe, North America, Asia (China), and other markets to capture regional demand and minimize single-market risk.

Ypsomed Holding AG (0QLQ.L): How It Works

• Primary revenue streams:
  • Sale of pen and autoinjector systems (devices and disposable cartridges)
  • Consumables and accessories (needles, cartridges, lancets)
  • Development & manufacturing services for pharma partners (device-drug combination projects)
  • After-market services, training and technical support

• Delivery Systems segment: product sales and development/manufacturing contracts form a major revenue base; technical know‑how enables platform licensing and customized device programmes.
• Diversified client base reduces concentration risk-no single client accounts for more than 15% of group revenue.
• Strategic focus on high‑margin delivery systems following the divestiture of the Diabetes Care division in April 2025, reallocating resources to biopharma partnerships and GLP‑1 support.
• Broad pharma engagement: agreements with 31 companies to support GLP‑1 drugs position Ypsomed to capture device demand from that expanding therapeutic wave.
• Capacity investments and geographic market expansion support scaling of commercial supply and bespoke manufacturing for large pharma programmes.

• Device sales: one‑time device revenues plus recurring disposable sales tied to patient use frequency.
• Contract development & manufacturing (CDMO): milestone and project fees, long‑term supply contracts with pharma partners.
• Platform licensing: upfront licenses and volume‑linked royalties for OEM partners adopting Ypsomed platforms.
• Service & support: training, regulatory support and connectivity services (where offered) add annuity‑style income.

• Higher-margin focus: divestiture of Diabetes Care concentrates capital and R&D on delivery systems and CDMO contracts that typically carry better margins than low‑margin legacy diabetes disposables.
• Revenue diversification: broad pharma partner base plus recurring consumable demand reduces volatility and supports predictable cash flows.
• Capacity-led growth: investment in manufacturing capacity and geographic expansion is expected to convert platform deals and GLP‑1 agreements into scalable volume revenue and market share gains.

Ypsomed Holding AG (0QLQ.L): How It Makes Money

• Core revenue drivers: sale of pen injectors, autoinjectors, infusion systems, and recurring consumables (cartridges, accessories).
• Partnering model: design, co-development and manufacturing contracts with pharma/device partners that secure long-term supply and licensing fees.
• Service & digital add-ons: device connectivity, data services, and patient support solutions that increase lifetime customer value.

• Market position: strong presence in medical technology self-medication segment with scalable platform products and recyclable materials that attract pharma partners seeking sustainable device solutions.
• Growth trajectory: high-margin focus and capacity expansion underpin mid-term ambition to double sales and sustain >30% EBIT margin.
• Capital deployment: CHF 1.5 billion capex aimed at tripling output to meet anticipated demand from partners and direct markets.